Efficacy of dose escalation in Chinese patients with advanced GIST after 400mg imatinib resistance

Efficacy of dose escalation in Chinese patients with advanced GIST after 400mg imatinib resistance: a prospective study

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-09000585

Enrollment

Unknown

Registered

2009-11-11

Start date

2004-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal stromal tumor

Interventions

Group A:imatinib dose escalation treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients (age >=18y) with a histologically confirmed recurrences or metastatic gastrointestinal stromal tumors; 2. Expressed CD117 positive; 3. Failed prior imatinib 400mg/d treatment are eligible for the trial.

Exclusion criteria

Exclusion criteria: 1. Patients with severe hematologic disorder, severe renal, hepatic, cardiovascular or pulmonary function impairment, or active infection requiring systemic antibiotics were excluded. were women with positive pregnancy test or who were breast-feeding.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Secondary

Measure	Time frame
Overall survival;	—

Countries

China

Contacts

Public ContactShen Lin

lin100@medmail.com.cn+86 010 88196175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026